BioLineRx Ltd ADR美股招股说明书(2025-07-25版)

statement on Form F-3 (File No. 333-276323), or the Registration Statement, as supplemented by our prospectus supplement, dated Statement pursuant to General Instruction I.B.5 of Form F-3. This prospectus supplement amends and supplements the information inthe Prior Prospectus relating to the offering, issuance and sale by us of our American Depositary Shares, or ADSs, representing our ordinary shares, par value NIS 0.10 per share, from time to time that may be issued and sold under the at-the-market offeringagreement, dated September 3, 2021, or the Offering Agreement, by and between us and H.C. Wainwright & Co., LLC, or Wainwright,as sales agent. This prospectus supplement should be read in conjunction with the Prior Prospectus, and is qualified by referencethereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectus. Thisprospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectus, andany future amendments or supplements thereto.As a result of these limitations and the current public float of our ordinary shares, including ordinary shares represented byADSs, and in accordance with the terms of the Sales Agreement, we may offer and sell ADSs having an aggregate offering price of up price of our ADSs on the Nasdaq was $4.51 per ADS. Our ordinary shares also trade on the Tel Aviv Stock Exchange, or TASE, underthe symbol “BLRX”. On July 24, 2025, the last reported sale price of our ordinary shares on the TASE was NIS 0.025 or $0.0075 pershare (based on the exchange rate reported by the Bank of Israel on the same day). General Instruction I.B.5. of Form F-3, was approximately $24.2 million. Pursuant to General Instruction I.B.5 of Form F-3, in noevent will we sell securities in a primary offering with a value exceeding more than one-third of our public float in any 12-monthperiod so long as our public float remains below $75,000,000. During the prior 12 calendar month period that ends on, and includes,the date of this prospectus supplement (excluding this offering), we sold securities with an aggregate market value of $3,194,586 will file another prospectus supplement prior to making such additional sales.Investing in our securities involves a high degree of risk. You should read this prospectus supplement and theaccompanying prospectus as well as the information incorporated herein and therein by reference carefully before you makeyour investment decision. See “Risk Factors” beginning on page S-5 of the ATM Prospectus and on page S-1 of theaccompanying prospectus, and the risk factors described in other documents incorporated by reference therein, to read aboutthe factors you should consider before investing in our securities. or complete. Any representation to the contrary is a criminal offense.H.C. Wainwright&Co.